A man with an HIV infection and secondary atypical hemolytic uremic syndrome (aHUS) was successfully treated with Soliris (eculizumab), a case study reported. “This case highlights the unusual presentation and [origin of aHUS], demonstrating the importance of recognizing therapeutic options in primary and secondary settings,” the researchers wrote…
News
Disease-causing variants in complement genes appear to be uncommon in children with atypical hemolytic uremic syndrome (aHUS) caused by autoantibodies against complement factor H (CFH), an Indian study found. The study, “Variants in complement genes are uncommon in patients with anti-factor H autoantibody-associated atypical hemolytic uremic syndrome,” was published…
Using Soliris (eculizumab) in combination with the blood cancer treatment obinutuzumab successfully prevented the recurrence of atypical hemolytic uremic syndrome (aHUS) after kidney transplant in a 45-year-old woman, a case study reported for the first time. The woman lost kidney function due to a rare occurrence of aHUS…
Vaccination against COVID-19 was linked to the onset or recurrence of atypical hemolytic uremic syndrome (aHUS) in three Dutch patients in a recent case report. Researchers didn’t find any additional cases wherein a vaccination could be tied to aHUS relapse in a retrospective analysis of 41 other aHUS patients…
Soliris (eculizumab) safely and effectively treated a 46-year-old man with atypical hemolytic uremic syndrome (aHUS) secondary to a scleroderma renal crisis — a life-threatening complication of an autoimmune disorder that can lead to kidney failure. His case was described in the study, “Atypical hemolytic-uremic syndrome due to a scleroderma renal crisis…
The demographics of people hospitalized for hemolytic uremic syndrome (HUS) in the U.S. have shifted over the last decade, with a lower proportion of young children and a higher number of Black patients, a new study reports. “Further surveillance is required to determine if these trends continue,” the researchers wrote.
CellCept (mycophenolate mofetil), an oral immunosuppressant used to prevent organ rejection, was effective in the treatment of a 10-year-old girl with severe atypical hemolytic uremic syndrome (aHUS). Researchers highlighted the importance of early diagnosis and careful monitoring in patient recovery. The study, “Atypical hemolytic uremic syndrome (aHUS)…
Two new mutations in the FHR2 gene were identified for the first time as the cause of severe atypical hemolytic uremic syndrome (aHUS) in a 24-year-old patient. After two years on dialysis, the man underwent a kidney transplant that was preceded by preventive treatment with Soliris (eculizumab) and…
Soliris (eculizumab) can safely be discontinued in children with atypical hemolytic uremic syndrome (aHUS) whose disease is in remission, but close monitoring is necessary due to the possibility of aHUS recurrence, a recent study in the Arabian Gulf region highlights. The study found that more than 70% of…
Soliris (eculizumab), an approved treatment for atypical hemolytic uremic syndrome (aHUS), is now available to patients in China, AstraZeneca announced. “This milestone reflects our ambition to bring transformative, rare disease medicines to the significant number of patients and families living with rare diseases in China who currently have…
Recent Posts
- Man’s psoriasis triggers kidney failure, aHUS in rare overlap
- How inflammation from multiple conditions led to an eye emergency
- Early treatment critical in aHUS to prevent lasting kidney damage
- I struggle daily with deconditioning from my multiple illnesses
- Complement inhibitors show edge over plasma at stopping aHUS relapses
- Boy’s kidney issues resolve after Soliris treatment: Case report
- I’m learning to say, ‘There’s always tomorrow’ when I’m feeling guilty
- Rare aHUS after kidney transplant successfully treated with Soliris
- Study describes ‘unusual trilogy’ of aHUS, Fabry disease, heart disorder
- My complicated health journey now includes post-exertional malaise